Combining anti-checkpoint immunotherapies and cancer vaccines as a novelstrategy in oncological therapy: A review
- سال انتشار: 1403
- محل انتشار: چهارمین همایش بین المللی زیست شناسی و علوم آزمایشگاهی
- کد COI اختصاصی: ZISTCONF04_024
- زبان مقاله: انگلیسی
- تعداد مشاهده: 175
نویسندگان
Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, Iran
Department of Pathology, School of Medicine, University of California, San Diego, USA
Department of Anatomical Sciences, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
Zoonotic Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran
Department of Occupational Health and Safety, School of Public Health and Safety, Shahid Beheshti University ofMedical Sciences, Tehran, Iran
چکیده
The fi eld of cancer immunotherapy has experienced remarkable advancements in the treatment of human cancersover recent decades. Therapeutic cancer vaccines have been employed to elicit antitumor immuneresponses through the generation of speci fi c reactions against tumor ‐ associated antigens. Although preclinicalstudies have demonstrated hopeful results and at least one product is approved for clinical use, the overall ef fi -cacy of cancer vaccines remains restricted. The co ‐ administration of anti ‐ checkpoint antibodies alongside cancervaccines is proposed as a potential strategy to enhance the clinical ef fi cacy of immunotherapies. Among thevarious anti ‐ checkpoint agents, monoclonal antibodies targeting CD۱۲۷, OX۴۰, and CD۴۰ have been furtherinvestigated in combined administration with cancer vaccines, demonstrating a synergistic impact on diseaseoutcomes in both animal models and human subjects. This combinational approach has been shown to suppresstumor regression, improve survival rates, and promote the ef fi cacy of cancer vaccines via multiple mechanisms,including the augmentation of generation, activation, and expansion of CD۸ + T cells, as well as the productionof tumor ‐ inhibitory cytokines. Importantly, the impact of the concurrent administration of anti ‐ checkpointagents and cancer vaccines surpass those observed with the sole vaccine, indicating that this strategy may offersigni fi cant advantages for clinical application in cancer patients. In this review, we aim to provide a comprehensiveoverview of the signi fi cance and therapeutic potential of the combined administration of checkpointagonist/antagonist antibodies and cancer vaccines for human tumors.کلیدواژه ها
cancer vaccineCheckpointImmunotherapyCD۱۲۷OX۴۰مقالات مرتبط جدید
- تولید آنتی بادی پلی کلونال مونواسپسیفیک جهت شناسایی باکتریهای جنس سالمونلا
- بررسی فراوانی سویه های مدرن و اجدادی مایکوباکتریوم توبرکلوزیس بر اساس نشانگر TbD۱ در شمال غرب ایران
- The impact of the gut microbiome on metabolic, psychiatric, and immune diseases
- پیشگیری از سرطان خون سفری به سوی زندگی سالمتر
- Investigating the Effect of Pulegone and Neomenthol Compounds in Cancer Inhibition Using Molecular Docking
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.